Overview

Pancuronium bromide is a steroidal, non-depolarizing neuromuscular blocking agent commonly used as a surgical muscle relaxant. It is not an anesthetic or analgesic; instead it blocks transmission at the neuromuscular junction so that skeletal muscles become temporarily paralyzed. The drug is widely referenced in clinical practice under its generic name and by the trade name Pavulon. For general information about its classification, see drug classes and clinical references in medicine.

Pharmacology and characteristics

Pancuronium competes with acetylcholine at nicotinic receptors on the motor end plate, preventing muscle contraction. It is considered relatively long-acting compared with some other neuromuscular blockers and may have cardiovascular effects such as tachycardia due to vagolytic activity. Because it is primarily eliminated by the kidneys, its duration may be prolonged in patients with renal impairment. Reversal of its effect in clinical settings is achieved with cholinesterase inhibitors (for example neostigmine) given with an antimuscarinic agent to offset muscarinic side effects.

Clinical uses and administration

In anesthesia, pancuronium is used to facilitate endotracheal intubation, provide muscle relaxation during surgery, and enable mechanical ventilation. Administrators monitor neuromuscular function with peripheral nerve stimulators to titrate dose and determine recovery. Important safety considerations include ensuring adequate sedation and analgesia before administering a paralytic and maintaining airway control throughout its action.

Adverse effects and precautions

  • Cardiovascular: possible increases in heart rate and blood pressure.
  • Respiratory: respiratory paralysis if ventilation is not supported.
  • Prolonged blockade in renal impairment.
  • Allergic reactions: uncommon but possible.

Because pancuronium causes paralysis without affecting consciousness, its use requires careful monitoring and should follow established perioperative safety protocols.

History, nonmedical uses, and controversy

Pancuronium has a long history in clinical anesthesia and intensive care. Outside medicine its most contentious role has been in assisted dying and capital punishment. The drug has been employed in some euthanasia protocols and, notably, in a three-drug sequence used for executions in the United States. In that protocol, a sedative is given first, pancuronium is given to induce paralysis, and potassium chloride is used to stop the heart; the three-drug approach is sometimes described as the three-drug protocol. These nonmedical applications have generated ethical, legal and professional debate because a paralytic can mask signs of consciousness during an execution or assisted death. Discussions of euthanasia and related topics can be found via resources on euthanasia.

The deployment of pancuronium outside clinical care, for example in executions of prisoners by lethal injection, has led to restrictions, manufacturer objections and policy changes in some jurisdictions. Medical societies generally discourage participation of healthcare professionals in executions. Within clinical practice, selection of neuromuscular blockers takes into account duration, side effect profile and patient comorbidities; alternatives such as vecuronium or rocuronium may be preferred in certain cases.

For more detailed prescribing information and regulatory status consult formal drug monographs and national treatment guidelines or the references linked above (classification, brand information, medical use).